DexCom (DXCM) Heads To A Healthcare Conference, Is The Stock Still A Bargain?

DexCom (DXCM) heads into its Wells Fargo healthcare conference appearance on 9 September with fresh attention on the stock after July’s Q2 report, when revenue rose 13.1% and shares jumped about 12%.

Over the past few months, DexCom’s share price has given back some of that July excitement, with a 7 day share price return of down 6.5% and a 30 day move of down 4.3%. However, the 90 day share price return of 11.5% and year to date share price return of 26.1% point to momentum that has cooled rather than reversed. At the same time, the 1 year total shareholder return of 10.4% and 3 and 5 year total shareholder returns that are still in decline show how recent optimism is set against a tougher longer term experience for investors.

Scan beyond DexCom and identify other potential healthcare momentum stories using our hand-picked screener of 17 high quality undiscovered gems that have strong fundamentals but still sit off most investors' radar.

DexCom now sits between a cooling share price and fresh excitement after Q2. Do you pay up for that momentum today, or wait for a cleaner entry point as the valuation picture comes into focus next?

Most Popular Narrative: 10.9% Undervalued

DexCom's most followed narrative pins fair value at $94.12 against a last close of $83.88, which frames the current gap the market is leaving on the table.

The recent expansion of insurance reimbursement for type 2 non-insulin diabetes patients, now covering nearly 6 million lives across the three largest U.S. PBMs, opens a large, previously untapped segment of DexCom's addressable market, which may drive new patient growth and support multi-year revenue expansion.

Growing global recognition of CGM efficacy, with recent clinical trial evidence and expanded coverage in international markets (e.g., France, Japan, and Ontario, Canada), may position DexCom to penetrate underpenetrated regions and diversify revenue streams.

Read the complete narrative.

Want a clearer picture of why this narrative leans toward a higher value for DexCom? The model leans on assumptions of steady top line expansion, higher margins, and a future earnings multiple that assumes investors continue to pay a premium for this kind of profile. You may want to review which specific revenue and profit assumptions sit under that fair value line and how far they extend into the future.

Result: Fair Value of $94.12 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the DexCom story can change quickly if competitive bidding compresses CGM pricing or if rivals gain share with new sensor technology.

Find out about the key risks to this DexCom narrative.

Another View: DexCom Through The P/E Lens

The SWS DCF model points to DexCom trading about 40.5% below an estimated future cash flow value of $141.04, which leans toward an undervalued story. Yet the market is already paying a P/E of 31.7x, above both the US Medical Equipment industry at 25.8x and peers at 24.3x, and only slightly under the fair ratio of 32.9x. This raises the question of whether the shares represent a bargain in the making or a full price for quality.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Curious whether the tone around DexCom in this analysis matches your own instincts on the stock’s potential rewards? Spend a few minutes with the underlying data, weigh the trade offs for yourself, then see how those positives line up in our 3 key rewards

Looking for more investment ideas beyond DexCom?

If DexCom has sharpened your interest in quality opportunities, use the Simply Wall Street Screener to uncover other stocks that fit your style and risk comfort.

• Target resilient compounding potential with companies that combine quality metrics and attractive pricing in our hand picked set of 31 high quality undervalued stocks.
• Prioritise sleep at night stability by focusing on businesses with stronger finances in the list of solid balance sheet and fundamentals (24 results) that can better handle tougher conditions.
• Limit downside surprises by focusing on companies with more resilient profiles using our 10 resilient stocks with low risk scores before capital chases the next obvious story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com